Benefits
Bowel regularity and digestive comfort
B. subtilis DE111 supplementation in adults with occasional gastrointestinal irregularity supported more normal stool frequency and consistency and reduced GI discomfort. A 90-day RCT in 50 adults with occasional constipation and/or diarrhea (Cuentas et al. 2017, J Probiotics Health) reported an increased frequency of normal-type stools and less GI discomfort versus placebo. No DE111 trial has been conducted specifically in people with diagnosed IBS.
Athletic recovery and immune support in athletes
In a trial of Division I baseball players (Townsend et al. 2018), DE111 supplementation was associated with lower TNF-α versus placebo (p = 0.024); a separate trial in female athletes (Toohey et al. 2020) found a greater reduction in body-fat percentage. Effects on upper-respiratory infections, CRP, and lactate clearance have not been demonstrated for this strain.
Shelf-stable probiotic for non-refrigerated environments
Unlike Lactobacillus and Bifidobacterium species (which require refrigeration to maintain viability), B. subtilis spores survive room temperature for years, withstand cooking temperatures (used in baked goods), and pass through stomach acid intact. This makes it the practical choice for travel, ambient-stored gummies, protein bars, and beverages.
Immune system training and infection resistance
B. subtilis spores germinate in the small intestine and interact with gut-associated lymphoid tissue (including Peyer's patches) during transit, which is proposed to support immune signaling. Human data on specific markers are limited: in a controlled athlete trial, salivary IgA rose over time but did NOT differ between DE111 and placebo. Effects on NK-cell activity and T-regulatory cells have not been established for this strain.
Mechanism of action
Spore-forming survival in extreme conditions
B. subtilis forms metabolically inactive endospores that survive 100°C+ heating, gastric acid (pH 1–2), bile salts, and years of room-temperature storage. Spores germinate to active vegetative form upon reaching the small intestine, where temperature, hydration, and nutrient availability trigger metabolic awakening.
Surfactin and bacillaene production — broad antimicrobials
B. subtilis produces dozens of antimicrobial compounds including surfactin (lipopeptide with surfactant + antimicrobial properties), bacillaene, subtilosin, and bacillibactin. These suppress pathogenic bacteria (C. difficile, S. aureus, E. coli), fungi (Candida species), and even some viruses through membrane disruption and metabolic interference.
Digestive enzyme production
B. subtilis secretes extracellular proteases, amylases, lipases, and cellulases that supplement host digestive enzymes. This enhances breakdown of proteins, complex carbohydrates, fats, and fibers in the small intestine — particularly beneficial for individuals with subclinical pancreatic insufficiency or aging-related digestive enzyme decline.
Quorum sensing modulation
B. subtilis disrupts quorum sensing in pathogenic bacteria — preventing them from coordinating virulence factor expression and biofilm formation. This is particularly relevant against C. difficile and pathogenic E. coli that rely on quorum sensing for tissue damage.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Bacillus subtilis DE111 (1 billion CFU/day) vs placebo in healthy adults experiencing occasional GI discomfort, over 4-12 weeks. Outcomes: stool consistency (Bristol scale), stool frequency, GI symptoms.
Healthy adults with occasional GI complaints.
DE111 supplementation associated with improved stool consistency normalization, reduced incidence of constipation/diarrhea episodes, and reduced bloating vs placebo. Note: the bowel-regularity literature for B. subtilis DE111 includes multiple small trials with consistent direction of effect; the largest peer-reviewed trial is Cuentas et al. 2017 (J Probiotics Health) and Labellarte/Maher 2019.
10-week, randomized, double-blind, placebo-controlled trial in 23 collegiate female athletes during offseason resistance training. DE111 (5 billion CFU/day) or placebo, with measurements of strength, performance, and body composition. (Toohey et al. 2020, J Strength Cond Res 34(11):3173-3181)
Collegiate female athletes during competitive season.
DE111 group showed a significantly greater reduction in body fat percentage than placebo (group × time interaction p = 0.015; DE111 −2.05% vs placebo −0.2%) when combined with post-workout nutrition; strength and performance improved over time in both groups. This trial did not measure TNF-α, sick days, or upper-respiratory infections. Generally well tolerated.